Welcome to the e-CCO Library Archive!

Filter:
P346. Profile of Belgian pediatric Crohn's disease patients: Presentation and diagnostic features
P346. The experience of restorative proctocolectomy for ulcerative colitis during 1985–2009
Authors:

I. Nieminen1, H. Huhtala2, M. Hyöty1, P. Collin1, P. Aitola1, 1Tampere University Hospital, Gastroenterology and alimentary tract surgery, Tampere, Finland, 2University of Tampere, Finland

P346

Early treatment with infliximab for Crohn's disease patients

Authors:

G. Pineton de Chambrun*1, L. Libier2, M. Nachury2, M. Collins3, D. Koriche4, C. Gower-Rousseau5, P. Zerbib4, A. Cortot6, J.-F. Colombel7, P. Desreumaux2

1Montpellier 1 University, Gastroenterology and Hepatology, Montpellier, France, 2CHU de Lille, Department of Gastroenterology, Lille, France, 3APHP Paris Sud University , Gastroenterology, Le Kremlin Bicêtre, France, 4Lille University Hospital, Colorectal Surgery Department , Lille, France, 5Lille University Hospital, North of France University, Epidemiology, Lille, France, 6Lille University Hospital, North of France University, Gastroenterology, Lille, France, 7Mount Sinai Hospital, Gastroenterology, New-York, United States

P347.

Severe scalp and skin involvement in Crohn's disease patients under treatment with anti-tumor necrosis factor alpha

Authors:

E. Rodrigues-Pinto1, F. Magro1, F. Osório2, S. Lopes1, S. Magina2, G. Macedo1, 1Centro Hospitalar São João, Gastroenterology Department, Porto, Portugal, 2Centro Hospitalar São João, Dermatology, Porto, Portugal

P347. Collagenous colitis: The clinical response after therapy with budesonide plus mesalazine and maintenance with mesalazine
P347. Epidemiological study of perianal fistulas in patients with Crohn's disease
P347. The efficacy of ganciclovir therapy in patients with steroid-refractory ulcerative colitis and cytomegalovirus infection
Authors:

M.K. Choi1, G.A. Song1, D.U. Kim1, D.Y. Ryu1, 1Pusan National University College of Medicine, Internal Medicine, Busan, South Korea

P347

Patient perception towards faecal microbiota transplantation for treatment of Inflammatory Bowel Disease

Authors:

N. Quraishi1, M. McMillan1, M. Widlak*1, L. Nell1, K. Quraishi2, S. Pathmakanthan1, N. Sharma2, T. Iqbal1

1University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital, Gastroenterology, Birmingham, United Kingdom, 2Heart of England NHS Foundation Trust, Heartlands Hospital, Gastroenterology, Birmingham, United Kingdom

P348.

Serum infliximab levels and early mucosal healing in Crohn's disease

Authors:

J. Tang, X. Gao, M. Zhi, H. Zhou, H. Chen, M. Zhang, Q. Yang, Z. Liang, The Sixth Affiliated Hospital of Sun Yat-sen University, Department of Gastroenterology, Guangzhou, China

P348. Retesting for latent tuberculosis in patients with inflammatory bowel disease after exposure to biologics
P348. The efficacy and safety of infliximab therapy in Korean patients with Crohn's diseases: a retrospective, multicenter study
Authors:

C.H. Choi1, K.H. Lee1, S.K. Chang1, W.H. Kim2, Y.H. Kim3, 1Chung-Ang University College of Medicine, Internal Medicine, Seoul, South Korea, 2Yonsei University College of Medicine, Internal Medicine, Seoul, South Korea, 3Sungkyunkwan University College of Medicine, South Korea

P348

How could female infertility be reduced after open IPAA

Authors:

T. Emmanouil*1, C. Christou2, A. Chatziioannou3, E. Falidas2, C. Vardas2, N. Kontoravdis2, S. Baratsis2

1Iaso General Hospital, Department of Gastroenterology and Surgery, Athens, Greece, 2Iaso General Hospital, Department of Gastroenterology and Surgery, Athens, Greece, 3National Hellenic Research Foundation, Institute of Biological Research &Biotechnology, Athens, Greece

P349.

Serum calprotectin: a novel biomarker to predict outcome in acute severe ulcerative colitis?

Authors:

N.C. Hare1,2, N.A. Kennedy2,3, R. Kalla2,3, K. Kingstone4, I.D.R. Arnott2, A.G. Shand2, K. Palmer2, I. Penman5, C.W. Lees2,3, J. Satsangi2,3, 1Taunton and Somerset NHS Foundation Trust, Department of Gastroenterology, Taunton, United Kingdom, 2Western General Hospital, Gastrointestinal Unit, Edinburgh, United Kingdom, 3University of Edinburgh, Gastrointestinal Unit, Centre for Genomic and Experimental Medicine, Edinburgh, United Kingdom, 4Western General Hospital, Department of Clinical Biochemistry, Edinburgh, United Kingdom, 5Royal Infirmary of Edinburgh, Endoscopy Unit, Centre for Liver and Digestive Disorders, Edinburgh, United Kingdom

P349. Profile of Belgian pediatric Crohn's disease (CD) patients: Associations between variables at diagnosis
P349. Risk of lymphoma in patients with inflammatory bowel disease: A Korean single-center study
P349. The effect of ulcerative colitis (UC) remission status after 8 weeks of induction therapy with MMX® mesalazine on long-term maintenance therapy outcomes (MOMENTUM Study): induction phase results
Authors:

G. D'Haens1, D.T. Rubin2, S. Inglis3, E. Magee4, P. Streck4, D. Solomon4, on behalf of the Ulcerative Colitis Remission Study Group, 1Academic Medical Center, Amsterdam, Netherlands, 2University of Chicago Inflammatory Bowel Disease Center, Chicago, IL, United States, 3Shire Pharmaceutical Development Ltd, Basingstoke, United Kingdom, 4Shire Development LLC, Wayne, PA, United States

P349

Consensus Statements on the Management of Acute Severe Ulcerative Colitis

Authors:

J.-H. Chen1, C. Corte1, V. Kariyawasam2, N. Moran1, P. Gounder1, G. Collins1, S. Connor3, T.W. Lee4, A. Walsh5, C.E. Koh6, 7, J. Chang1, S. Paramsothy8, S. Tattersall9, D.A. Lemberg10, 11, A. McLachlan12, 13, G. Moore14, J. Andrews15, R. Leong*1

1Concord Repatriation General Hospital, Gastroenterology & Hepatology, Sydney, Australia, 2Blacktown Hospital, Gastroenterology & Hepatology, Sydney, Australia, 3Liverpool Hospital, Gastroenterology & Hepatology, Sydney, Australia, 4Wollongong Hospital, Gastroenterology & Hepatology, Wollongong, Australia, 5St. Vincent Hospital, Gastroenterology & Hepatology, Sydney, Australia, 6Royal Prince Alfred Hospital, Colon & Rectal Surgery, Sydney, Australia, 7Royal Prince Alfred Hospital, Surgical Outcomes Research Centre, Sydney, Australia, 8University of New South Wales, St Vincent's Clinical School, Faculty of Medicine, Sydney, Australia, 9Ryde Hospital, Gastroenterology, Sydney, Australia, 10Sydney Children's Hospital, Paediatric Gastroenterology, Sydney, Australia, 11University of New South Wales, Woman's and Children's Health, Sydney, Australia, 12The University of Sydney, Faculty of Pharmacy, Sydney, Australia, 13Concord Repatriation General Hospital, Centres for Education and Research on Ageing, Sydney, Australia, 14Monash University & Monash Health, Gastroenterology & Hepatology, Clayton, Melbourne, Australia, 15Royal Adelaide Hospital, Gastroenterology and Hepatology, Adelaide, Australia

P350.

Serum CRP is a better early marker for response to infliximab induction therapy than fecal calprotectin in patients with moderate to severe ulcerative colitis

Authors:

J.F. Brandse1, J.M. Jansen2, P.A. Baars3, M. Löwenberg1, C.Y. Ponsioen1, G.R. van den Brink1, G. D'Haens1, 1Academic Medical Center, Inflammatory Bowel Disease Centre, Amsterdam, Netherlands, 2Onze Lieve Vrouwe Gasthuis, Gastroenterology and Hepatology, Amsterdam, Netherlands, 3Academic Medical Center, Clinical Immunology, Amsterdam, Netherlands

P350. Incidence of inflammatory bowel disease in Kaunas region, Lithuania: A prospective three year study
P350. Long term outcome of endoscopic balloon dilatation of anastomotic strictures in patients with Crohn's disease